Off-label use in palliative medicine

被引:0
作者
Remi, Constanze [1 ]
Gerlach, Christina [2 ]
机构
[1] Klinikum Univ Munchen, Klin & Poliklin Palliat Med, Arzneimittelinformat, Marchioninistr 15, D-81377 Munich, Germany
[2] Univ Klinikum Hamburg Eppendorf, Med Klin & Poliklin Onkol Hamatol Knochenmark Tra, Abt Pneumol, Bereich Palliat Med,Zentrum Onkol 2, Hamburg, Germany
来源
SCHMERZ | 2021年 / 35卷 / 01期
关键词
Hospices; Terminal care; Drug approval; Remuneration; drug therapy; Documentation; treatment; Palliative Care;
D O I
10.1007/s00482-020-00522-5
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Palliative care serves to improve the quality of life in patients suffering from incurable diseases. Pharmacotherapy of distressing symptoms plays an important role. Off-label use refers to the use of drugs outside the marketing authorization. In addition to the indications off-label use may also be due to duration of treatment, route of administration and the admixture of substances. Off-label use is common in palliative and hospice care and is probably unavoidable in many cases. For treatment planning and realization of off-label therapy in clinical practice, patient-related aspects, information, therapy monitoring and documentation of therapy effects should be considered in addition to drug-related information. Only in this way it is possible to offer a scientifically adequate, appropriate and economic therapy that is linked to an appropriate risk-benefit ratio for the individual patient. Due to the lack of authorization studies, reporting is of particular importance.
引用
收藏
页码:61 / 73
页数:13
相关论文
共 22 条
[1]   Off-label and unlicensed prescribing in Europe: implications for patients' informed consent and liability [J].
Aagaard, Lise ;
Kristensen, Kent .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (03) :509-512
[2]  
[Anonymous], 2015, WHO definition of palliative care
[3]   Off-Label and Unlicensed Drugs in Pediatric Palliative Care: A Prospective Observational Study [J].
Garcia-Lopez, Isabel ;
Cuervas-Mons Vendrell, Margarita ;
Martin Romero, Irene ;
de Noriega, Inigo ;
Benedi Gonzalez, Juana ;
Martino-Alba, Ricardo .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2020, 60 (05) :923-932
[4]  
Golocorbin Kon Svetlana, 2015, Med Pregl, V68, P35
[5]  
Gore R, 2017, CURR CLIN PHARMACOL, V12, P18, DOI 10.2174/1574884712666170317161935
[6]  
Häuser W, 2019, BUNDESGESUNDHEITSBLA, V62, P836, DOI 10.1007/s00103-019-02966-2
[7]   Off-label-prescriptions in daily clinical practice - a cross-sectional national survey of palliative medicine physicians [J].
Hagemann, Vera ;
Bausewein, Claudia ;
Remi, Constanze .
PROGRESS IN PALLIATIVE CARE, 2019, 27 (04) :154-159
[8]   Drug use beyond the licence in palliative care: A systematic review and narrative synthesis [J].
Hagemann, Vera ;
Bausewein, Claudia ;
Remi, Constanze .
PALLIATIVE MEDICINE, 2019, 33 (06) :650-662
[9]   Off-label therapy: current problems from the perspective of the Pharmaceutical Commission of the German Medical Profession [J].
Janzen, R. W. C. ;
Ludwig, W. D. .
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2012, 71 (02) :108-+
[10]   Opioids for breathlessness: a narrative review [J].
Johnson, Miriam J. ;
Currow, David C. .
BMJ SUPPORTIVE & PALLIATIVE CARE, 2020, 10 (03) :287-295